1BP-LSD is the newest LSD derivative on the research chemicals market and has generated considerable discussion within our research community since its introduction in 2025. If you want to know what makes this substance chemically distinctive, how it works, which forms are available, and how it compares — you are in exactly the right place.

I am Kai, and over the past months I have compiled all available data on 1BP-LSD: community reports, analytical data, and comparisons with earlier derivatives. What follows is arguably the most thorough factsheet on this substance you will find.

1BP-LSD belongs to the family of N1-acylated LSD prodrugs — a substance class that has been systematically researched since 2014. The distinguishing feature: at the nitrogen-1 position of the indole ring, 1BP-LSD carries a butyryl-propionyl group. That might sound like chemical jargon, so let me break it down.

What Is a Butyryl-Propionyl Group?

Imagine the LSD-25 molecule as a complex building. At a specific location — the N1 nitrogen — this building has an open door. In 1BP-LSD, a kind of airlock has been built in front of this door: the butyryl-propionyl group. This airlock consists of two linked fatty acid chains (butyric acid and propionic acid).

This dual-acyl structure is a first: earlier derivatives such as 1P-LSD (propionyl), 1cP-LSD (cyclopropionyl), or 1V-LSD (valeryl) each carried only a single acyl group. 1BP-LSD is the first to combine two different fatty acid residues in a single side chain. The molecular weight of 449.6 g/mol thus falls between 1V-LSD (435.6 g/mol) and 1Fe-LSD (over 500 g/mol).

The Prodrug Mechanism

Like all N1-acyl LSD derivatives, 1BP-LSD is a prodrug: the substance itself has no significant affinity for the 5-HT2A receptor. Only after ingestion do endogenous enzymes (primarily hepatic esterases in the liver) cleave the butyryl-propionyl group. What remains is LSD-25 — the active metabolite.

This conversion process explains three characteristic properties of 1BP-LSD:

1. Delayed onset: Metabolisation takes time. Expect 45-75 minutes until the first effects — sometimes longer.
2. Gentler onset: Rather than an abrupt "switch," many researchers describe a gradual arrival.
3. Possible nuances in effects: Although the end metabolite is identical, some researchers report subtle differences in the experience profile. This could be due to the metabolisation kinetics — the speed at which LSD-25 is released influences receptor occupancy dynamics.

Brandt et al. (2017) demonstrated conversion rates of 85-95% into the active metabolite for predecessor derivatives. Controlled studies for 1BP-LSD are still pending, but community data suggest comparable efficiency.

1BP-LSD is available in three forms — each with its own advantages. Here is my honest ranking:

Blotters

The classic form. 1BP-LSD is applied to perforated, absorbent paper.

Administration: Sublingual (place under the tongue, hold for 15-20 minutes, then swallow). Sublingual absorption through the oral mucosa accelerates the onset by approximately 10-15 minutes compared to swallowing directly.

Advantages: Discreet, easy to store, precisely dosed, long shelf life with correct storage.

Disadvantages: Splitting for intermediate doses is imprecise (half a blotter is not exactly half the dose — distribution on the paper is not always homogeneous).

Pellets (Micro-Tablets)

Small, pressed tablets — and in my opinion the best innovation in recent years for microdosing research.

Administration: Orally with some water. It does not get simpler.

Advantages: Extremely precise dosing, ideal for microdosing protocols, no preparation needed.

Disadvantages: Not usefully divisible. For full research sessions you would need many pellets — impractical and expensive.

Drops

Liquid solution in a dropper bottle.

Administration: Drops placed directly on the tongue or dissolved in water.

Advantages: Maximally flexible dosing. You can dose to microgram precision if you know the drop volume and the solution concentration.

Disadvantages: Requires careful handling. Drop size varies depending on bottle angle and solution temperature. Error-prone for beginners.

Kai's assessment: Drops are excellent for experienced researchers who want to dose volumetrically. For beginners, I would always recommend blotters (for full sessions) or pellets (for microdosing).

This is where it gets exciting — and simultaneously complex. Because although 1BP-LSD is a prodrug that converts to LSD-25, researchers do report a distinct character. Whether this is due to metabolisation kinetics, individual expectation effects, or actual pharmacological nuances — science does not yet have a definitive answer.

The Phases in Detail

Onset: 45-75 minutes
Longer than some predecessor derivatives. The butyryl-propionyl group must first be enzymatically cleaved. Initial signs: slight change in colour perception, a sense of "alertness," sometimes mild stomach unrest (in approximately 20-30% of researchers, according to community data).

Come-Up: 1-2.5 hours
Effects intensify gradually. Community reports describe the come-up of 1BP-LSD as particularly gentle and smooth — less "jerky" than, say, 1P-LSD. Emotional openness increases, visual perception changes.

Peak: 2.5-5 hours
The phase of strongest effects. At 100 micrograms: clear visual changes, intensified emotions, altered time perception, increased creativity and associative thinking. At 200 micrograms: significantly more intense, deeper altered states of consciousness, stronger visual effects.

Plateau: 5-8 hours
Intensity decreases slightly but remains at a stable level. Many researchers describe this phase as the "most pleasant" — the initial excitement has passed, the effects are familiar, and the experience can be consciously explored.

Offset: 8-12 hours
Slow, gradual fading. No abrupt ending. After approximately 10-12 hours, most of the effects have subsided. Mild residual effects (increased alertness, subtle perceptual changes) may persist for another 2-3 hours.

Effect Overview Table

Kai's Assessment

1BP-LSD has established itself as a solid derivative within just a few months. Its strengths clearly lie in the gentle onset and the excellent microdosing suitability through the pellet form. Compared to 1Fe-LSD, I see the advantage in the somewhat faster onset — if you do not want to wait 90 minutes for the effects to begin, 1BP-LSD is the better choice.

One minor drawback: the data is still thin. We have only a few months of community data, and controlled studies are entirely absent. This is not a dealbreaker — the same was true for every new derivative in the beginning — but it means you should document your own experiences carefully. You are part of the research.

As of 2025/2026, 1BP-LSD is available as a research chemical in Germany. It falls neither under the Narcotics Act (BtMG) nor — based on the current situation — under the New Psychoactive Substances Act (NpSG). However, the legal status may change, and the legal situation varies from country to country.

Important: Always check the current legal status in your country. What is legal today may look different tomorrow. Trustworthy vendors provide information about the current status on their websites.

Based on available community data and experience with related derivatives:

*Note: Blotter splitting is imprecise. For accurate intermediate doses, I recommend volumetric dosing with drops.

1BP-LSD takes its place as a worthy successor in the line of N1-acylated LSD prodrugs. The butyryl-propionyl side chain brings its own kinetic profile — whether that makes a noticeable difference in practice depends on individual metabolism.

What convinces me:

• Gentle, gradual onset
• Outstanding microdosing pellets (10 and 20 mcg)
• Broad range of available forms
• Good safety profile (as far as current data shows)

What I still wish for:

• More controlled data on conversion rates
• Long-term community data (will come with time)
• Pharmacological studies on metabolisation kinetics

If you are looking for a current, readily available LSD derivative — whether for microdosing or full research sessions — 1BP-LSD is definitely a well-founded choice.

And now go research. But with good sense, please.